223 related articles for article (PubMed ID: 27357866)
1. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
Balakirski G; Alkhateeb A; Merk HF; Leverkus M; Megahed M
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1778-1782. PubMed ID: 27357866
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
[TBL] [Abstract][Full Text] [Related]
3. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
[TBL] [Abstract][Full Text] [Related]
4. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
[TBL] [Abstract][Full Text] [Related]
6. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
Messingham KN; Pietras TA; Fairley JA
G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
[TBL] [Abstract][Full Text] [Related]
7. IgE autoantibodies in bullous pemphigoid: supporting role, or leading player?
Ujiie H
J Dermatol Sci; 2015 Apr; 78(1):5-10. PubMed ID: 25797172
[TBL] [Abstract][Full Text] [Related]
8. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
Front Immunol; 2019; 10():1919. PubMed ID: 31474990
[TBL] [Abstract][Full Text] [Related]
9. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
11. Research progress of omalizumab in the treatment of bullous pemphigoid.
Ling X; Shou X; Lou Y; Ling J; Zhang M; Yu T; Gu W
J Dermatol; 2023 May; 50(5):575-587. PubMed ID: 36971190
[TBL] [Abstract][Full Text] [Related]
12. [EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
Neumark M; Tal Y; Zlotogorski A; Molho-Pessach V
Harefuah; 2020 Jan; 159(1):29-30. PubMed ID: 31930804
[TBL] [Abstract][Full Text] [Related]
13. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases.
Moriuchi R; Nishie W; Ujiie H; Natsuga K; Shimizu H
J Dermatol Sci; 2015 Apr; 78(1):21-5. PubMed ID: 25724363
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
15. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.
Iwata Y; Komura K; Kodera M; Usuda T; Yokoyama Y; Hara T; Muroi E; Ogawa F; Takenaka M; Sato S
Arch Dermatol; 2008 Jan; 144(1):41-8. PubMed ID: 18209167
[TBL] [Abstract][Full Text] [Related]
16. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
van Beek N; Schulze FS; Zillikens D; Schmidt E
Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
[TBL] [Abstract][Full Text] [Related]
17. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
[TBL] [Abstract][Full Text] [Related]
18. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis.
Yayli S; Pelivani N; Beltraminelli H; Wirthmüller U; Beleznay Z; Horn M; Borradori L
Br J Dermatol; 2011 Nov; 165(5):1133-7. PubMed ID: 21711326
[TBL] [Abstract][Full Text] [Related]
19. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
